Oncolytics Biotech Inc. (TSE:ONC – Get Free Report)’s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$14.90 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares traded.
Oncolytics Biotech Price Performance
The business’s 50-day moving average is C$14.90 and its two-hundred day moving average is C$14.90. The company has a quick ratio of 8.86, a current ratio of 2.88 and a debt-to-equity ratio of 14.58. The stock has a market capitalization of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.
See Also
- Five stocks we like better than Oncolytics Biotech
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
